October 31, 2015 9:16am

 

We’re closing in on Halloween; financial results/earnings are considered a frightening prospect but, not scary as traders are betting with the short side

I ain’t feelin’ the love! Subscription required, read more … http://www.regmedinvestors.com/user/register

 

 

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

 

 

U.S. stocks ended lower Friday but closed out their best month in four years, helped by a recovery in oil prices and hopes of easy monetary policy.

The NASDAQ closed DOWN -20.53 or -0.40% to 5,053.75 and the DOW closed DOWN -92.26 or -0.52% to 17,663.54.

 

 

Henry’omics:

  • Friday had a down forecast as Thursday’s indexes and ETFs were depressed.

We continue to see selling gravity in stocks and buying anxiety as traders wipe clean the slate ahead of the weekend. Being gone is safer than being long!

  • There's just a whole lot of uncertainty as the month ends and financial results/earning releases are slated for next week.  

Volume has stayed low and volatility festered with pronouncement but, with more questions than answers about erratic movement of some stocks.

 

 

Riding the indexes and ETFs roller-coaster:

  • The iShares Biotechnology Stocks ETF (IBB) closed Friday DOWN -3.09 or -0.94% after Thursday closed down -3.24 or -0.98% following Wednesday’s +4.14 or +1.26% after Tuesday’s advance of +10.20 or +3.215 following Monday’s +1.17 or +0.37%;
  • The NASDAQ Biotechnology index (NBI) closed Friday down 31.55 or -0.92% following Thursday’s -26.88 or -0.77% post Wednesday’s  advance of +45.69 or +1.33% after Tuesday’s advance of +99.44 or +2.99% following Monday’s advance of +27.14 or +0.82%;
  • The Russell 2000 (IWM) closed down on Friday -0.43 or -0.46% after Thursday’s decline of -1.25 or -1.07% following Wednesday’s advance of  +3.32 or +2.92% after Tuesday’s decline of -1.26 or -1.10% following Monday’s decline of -0.79 or -0.68%;
  • The SPDR SD&P Biotech ETF (XBI) closed down on Friday -0.68 or -1.01% after Thursday’s decline of -1.78 or -2.58% following Wednesday‘s advance of +1.73 or +2.57% after Tuesday’s advance of +1.44 or +2.19% following Monday’s advance of +0.20 or +0.30%;

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

  • The SCGT & RM equities opened negative with an A/DL of 12/26 and 5 flats staying negative to the mid-day A/DL of 15/25 and 3 flats;
  • The closing bell rang negative to end the session with an A/DL of 14/27 and 2 flats.

My fear index, the CBOE Volatility Index (VIX) traded Friday’s near 15 following Thursday below 14 after Wednesday near 14 following Tuesday’s above 15 after Monday’s near 15.

 

 

Dosing the sector – what a day for the 43 Patients:

  • Open: NEGATIVE with 26 decliners, 12 advances and 5 flats;
  • Mid-day (1 pm): NEGATIVE with 25 decliners, 15 advancers and 3 flats;
  • Closing bell: NEGATIVE with 27 decliners, 14 advancers and 2 flats

 

 

Friday’s trading indications:  6 hits/ 3 miss

  • Applied Genetic Technology (AGTC) closed DOWN – miss;
  • Capricor (CAPR) closed DOWN – hit;
  • Histogenics (HSGX) closed DOWN – hit;
  • Juno Therapeutics (JUNO) closed UP – miss;
  • Ocata Therapeutics (OCATA) closed DOWN – hit;
  • MiMedx (MDXG) closed DOWN – miss;
  • Osiris (OSIR) closed UP – hit;
  • Sangamo (SGMO) closed DOWN – hit;
  • Verastem (VSTM closed UP – hit;

 

 

Who closed down – top 5:

  • Bluebird bio (BLUE) closed down -$1.96 to $77.13;
  • Spark Therapeutics ONCE) -$1.21 to $53.90;
  • Kite Pharma (KITE) -$0.72 to $68.05;
  • Sangamo (SGMO) -$0.64 to $7.05;
  • Bellicum (BLCM) closed down -$0.50 to $12.51

 

 

Who was UP – top 5:

  • Osiris (OSIR) closed up +$0.60 to $17.03;
  • Juno Therapeutics (JUNO) +$0.37 to $51.76;
  • Cellectis ADR (CLS) +$0.36 to $26.45;
  • AxoGen (AXGN) +$0.26 to $4.65;
  • ReNeuron (RENE.L) closed up +$0.13 to $3.875

 

 

Flat:

  • Mesoblast ADR (USOTC: MBLTY) at $12.33;
  • VistaGen (VSTA) at $7.49

 

 

All investments are subject to risks. Investors should consider investment objectives. The information included above as well as individual companies and/or securities mentioned should only construed as an indication from any RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.